Zymergen Acquires Lodo Therapeutics

LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

Pharmaceuticals

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.

Zymergen Acquires enEvolv

March 19, 2020

Biotechnology

Zymergen has acquired enEvolv, a synthetic biology company that provides ultra-high throughput microbial screening and engineering. The acquisition brings enEvolv's biosensor-driven platform and team into Zymergen to accelerate discovery and commercialization of biologically-manufactured materials across electronics, consumer care, agriculture and other end markets.

Zydus Lifesciences Acquires Agenus' U.S. Biologics Manufacturing Facilities and Launches Zylidac Bio LLC

January 16, 2026

Biotechnology

Zydus Lifesciences Limited has completed purchase agreements with Agenus Inc. to acquire Agenus' biologics manufacturing facilities and operations in Emeryville and Berkeley, California, and has established a U.S. CDMO subsidiary, Zylidac Bio LLC, to operate the assets. The deal includes exclusive manufacturing arrangements for Agenus' Phase 3 immuno-oncology candidates (botensilimab and balstilimab), exclusive commercialization rights for those assets in India and Sri Lanka, and an equity investment in Agenus via Zynext Ventures; regulatory approvals including CFIUS clearance were secured.

Altos Labs Acquires Dorian Therapeutics

May 23, 2025

Biotechnology

Altos Labs has acquired Stanford spinout Dorian Therapeutics, a preclinical senotherapeutics startup developing small-molecule "senoblockers." Financial terms were not disclosed; Altos said the deal broadens its cellular rejuvenation capabilities by adding Dorian’s epigenetic senescence-targeting technology and preclinical programs in lung fibrosis and osteoarthritis.

Lomond Therapeutics Completes Reverse Merger with Venetian-1 and Raises $44M

November 4, 2024

Biotechnology

Lomond Therapeutics completed a reverse merger with Venetian-1 Acquisition Corp., which changed its name to Lomond Therapeutics Holdings, Inc., and closed a $44 million private placement led by existing and new investors. The financing included participation from OrbiMed, Torrey Pines Investment, Deerfield Management, American Financial Group and Heights Capital and will fund advancement of Lomond’s clinical-stage oncology programs (lomonitinib, lonitoclax and a menin inhibitor).

Blueprint Medicines Acquires Lengo Therapeutics

November 29, 2021

Biotechnology

Blueprint Medicines has entered a definitive agreement to acquire privately held precision oncology company Lengo Therapeutics for $250 million in cash plus up to $215 million in regulatory- and sales-based milestones. The deal adds Lengo’s lead oral EGFR exon 20 insertion candidate LNG-451 and other preclinical precision oncology programs to Blueprint’s lung cancer portfolio, expanding its capability in brain-penetrant EGFR inhibitors.